Article
Taiho's RECOURSE Trial Meets Primary Endpoint for mCRC in Phase 3
Taiho Pharmaceutical Co., parent company of Taiho Oncology, announced recently that its combination drug for refractory metastatic colorectal cancer met its primary endpoint in a phase 3 global RECOURSE trial.
The RECOURSE trial of the combined oral drugs trifluridine and tipiracil hydrochloride (TAS-102) is a global, randomized, double blind, placebo-controlled study of 800 people with refractory mCRC. Each participant had received at least two prior failed treatment attempts using standard chemotherapy and received either TAS-102 or placebo to establish the efficacy and toleration of the drug combination and improve overall survival.
“We are very pleased by the results from the phase 3 RECOURSE trial in refractory mCRC, which support TAS-102 as a potential new treatment option for this patient population,” Fabio M. Benedetti, MD, senior vice president and chief medical officer at Taiho Oncology, said in a press release.
Report: http://bit.ly/1hK7lQD
Source: Healio
How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL
